The company has no funds in the bank; three of its four products have long been suspended due to lack of funds; and if that's not enough, the company has 190 million shares on issue - which will inevitably balloon to 250-300m if they are to raise necessary further capital.
Yet you speak of Virax as offering "leverage".
Leverage to the poor house if you ask me.
